MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jcrc.2023.154446

Медицинская библиотека · Journal of critical care · 2023

The safety and efficacy of stem cells for the treatment of severe community-acquired bacterial pneumonia: A randomized clinical trial.

Laterre Pierre-François, Sánchez García Miguel, van der Poll Tom, Wittebole Xavier, Martínez-Sagasti Fernando, Hernandez Gonzalo, Ferrer Ricard, Caballero Jesus, Cadogan Kathy-Ann, Sullivan Adam, Zhang Barbara, de la Rosa Olga, Lombardo Eleuterio, François Bruno, SEPCELL Study Group

Клиническое исследование I фазыКлиническое исследование II фазыСтатьяМногоцентровое исследованиеРандомизированное исследованиеПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

PURPOSE: Evaluate the safety profile of expanded allogeneic adipose-derived mesenchymal stem cell (eASC) for the treatment of severe community-acquired bacterial pneumonia (CABP).

MATERIALS AND

METHODS

Randomized, multicenter, double-blind, placebo-controlled, phase 1b/2a trial. Patients with severe CABP were enrolled to receive intravenous infusions of Cx611 or placebo. The primary objective was safety including hypersensitivity reactions, thromboembolic events, and immunological responses to Cx611. The secondary endpoints included the clinical cure rate, ventilation-free days, and overall survival (Day 90).

RESULTS

Eighty-three patients were randomized and received infusions (Cx611: n = 42]; placebo: n = 41]. The mean age was similar (Cx611: 61.1 [11.2] years; placebo: 63.4 [10.4] years). The number of AEs and treatment-emergent AEs were similar (243; 184 and 2; 1) in Cx611 and placebo respectively. Hypersensitivity reactions or thromboembolic events were similar (Cx611: n = 9; placebo: n = 12). Each study arm had similar anti-HLA antibody/DSA levels at Day 90. The clinical cure rate (Cx611: 86.7%; placebo: 93.8%), mean number of ventilator-free days (Cx611: 12.2 [10.29] days; placebo: 15.4 [10.75] days), and overall survival (Cx611: 71.5%; placebo: 77.0%) did not differ between study arms.

CONCLUSION

Cx611 was well tolerated in severe CABP. These data provide insights for future stem cell clinical study designs, endpoints and sample size calculation.

TRIAL REGISTRATION: NCT03158727 (retrospectively registered: May 09, 2017). Full study protocol: https://clinicaltrials.gov/ProvidedDocs/27/NCT03158727/Prot_000.pdf.

Для цитирования: Laterre Pierre-François, Sánchez García Miguel, van der Poll Tom, Wittebole Xavier, Martínez-Sagasti Fernando, Hernandez Gonzalo, Ferrer Ricard, Caballero Jesus, Cadogan Kathy-Ann, Sullivan Adam, Zhang Barbara, de la Rosa Olga, Lombardo Eleuterio, François Bruno, SEPCELL Study Group. The safety and efficacy of stem cells for the treatment of severe community-acquired bacterial pneumonia: A randomized clinical trial.. Journal of critical care. 2023. DOI: 10.1016/j.jcrc.2023.154446.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.